Bicara Therapeutics (NASDAQ:BCAX) Stock Price Target Cut by Morgan Stanley

Bicara Therapeutics (NASDAQ:BCAX) had its target price dropped by research analysts at Morgan Stanley from $41.00 to $30.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Morgan Stanley‘s price objective would indicate a potential upside of 199.91% from the company’s current price.

BCAX has been the subject of a number of other reports. The Goldman Sachs Group downgraded Bicara Therapeutics from a “neutral” rating to a “sell” rating and cut their price objective for the company from $20.00 to $8.00 in a research note on Friday, October 30th. Wedbush lowered their price target on shares of Bicara Therapeutics from $33.00 to $24.00 and set an “outperform” rating on the stock in a report on Thursday, October 29th. BMO Capital Markets began coverage on shares of Bicara Therapeutics in a research report on Tuesday, August 18th. They issued an “outperform” rating and a $35.00 price target for the company. Citigroup reissued a “market outperform” rating on shares of Bicara Therapeutics in a research note on Tuesday. Finally, BTIG Research decreased their price objective on shares of Bicara Therapeutics from $39.00 to $37.00 and set a “buy” rating on the stock in a research report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Bicara Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $30.83.

Bicara Therapeutics Trading Up 0.2%

NASDAQ:BCAX traded up $0.02 during mid-day trading on Tuesday, reaching $10.00. The company’s stock had a trading volume of 296,939 shares, compared to its average volume of 750,991. The firm’s fifty day moving average price is $17.89 and its two-hundred day moving average price is $20.91. Bicara Therapeutics has a 12-month low of $7.87 and a 12-month high of $30.99. The stock has a market cap of $661.90 million, a P/E ratio of -3.21 and a beta of -0.33.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings results on Monday, November 9th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.22). Analysts predict that Bicara Therapeutics will post -3.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Bicara Therapeutics

In other Bicara Therapeutics news, CEO Ryan Cohlhepp sold 17,500 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total transaction of $400,750.00. Following the transaction, the chief executive officer owned 181,641 shares in the company, valued at $4,159,578.90. The trade was a 8.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.80% of the company’s stock.

Institutional Trading of Bicara Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its holdings in Bicara Therapeutics by 33.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 44,425 shares of the company’s stock valued at $827,000 after buying an additional 11,086 shares in the last quarter. Nan Fung Trinity HK Ltd. grew its stake in Bicara Therapeutics by 49.9% in the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 427,885 shares of the company’s stock worth $7,963,000 after acquiring an additional 142,390 shares in the last quarter. Alps Advisors Inc. increased its position in shares of Bicara Therapeutics by 32.5% during the third quarter. Alps Advisors Inc. now owns 87,692 shares of the company’s stock worth $1,632,000 after acquiring an additional 21,510 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Bicara Therapeutics during the third quarter worth approximately $63,000. Finally, Profund Advisors LLC raised its stake in shares of Bicara Therapeutics by 7.2% during the third quarter. Profund Advisors LLC now owns 16,880 shares of the company’s stock valued at $314,000 after acquiring an additional 1,140 shares in the last quarter.

Bicara Therapeutics News Roundup

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Bicara said enrollment is substantial in its pivotal FORTIFI-HN01 trial, with interim-analysis results expected in mid-2027. It also reported $442.3 million in cash, which it expects to fund operations into the first half of 2029—supporting development plans while limiting near-term financing concerns. Bicara third-quarter results and business update
• Neutral Sentiment: Stifel Nicolaus cut its price target from $45 to $43 and BTIG Research lowered its target from $39 to $37. Both firms maintained “buy” ratings, leaving targets well above the current share price, though the reductions temper their outlooks. Stifel Nicolaus ratings BTIG Research ratings
• Negative Sentiment: BCAX reported a third-quarter loss of $1.04 per share, wider than the $0.82 loss analysts expected. The earnings miss may weigh on shares, particularly as the company remains clinical-stage and investors await trial results. Bicara third-quarter earnings report

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses.

The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.